Replimune Group (NASDAQ:REPL) PT Lowered to $48.00

Replimune Group (NASDAQ:REPL) had its target price decreased by research analysts at HC Wainwright from $50.00 to $48.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 327.81% from the stock’s current price. HC Wainwright also issued estimates for Replimune Group’s Q4 2025 earnings at ($0.93) EPS and FY2025 earnings at ($3.86) EPS.

Separately, Wedbush reissued an “outperform” rating and set a $52.00 price objective on shares of Replimune Group in a report on Wednesday, November 8th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $51.33.

Replimune Group Stock Performance

REPL opened at $11.22 on Monday. The firm has a market capitalization of $662.65 million, a P/E ratio of -3.64 and a beta of 1.63. The stock’s 50 day moving average price is $15.42 and its two-hundred day moving average price is $18.77. The company has a quick ratio of 12.76, a current ratio of 12.76 and a debt-to-equity ratio of 0.11. Replimune Group has a 12-month low of $10.42 and a 12-month high of $29.52.

Replimune Group (NASDAQ:REPL) last released its earnings results on Tuesday, November 7th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10). On average, equities analysts forecast that Replimune Group will post -3.46 earnings per share for the current year.

Insider Buying and Selling at Replimune Group

In other Replimune Group news, insider Pamela Esposito sold 5,358 shares of Replimune Group stock in a transaction on Monday, September 11th. The stock was sold at an average price of $20.01, for a total value of $107,213.58. Following the completion of the transaction, the insider now owns 263,436 shares in the company, valued at approximately $5,271,354.36. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 20.60% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Institutional investors and hedge funds have recently made changes to their positions in the company. Victory Capital Management Inc. raised its position in shares of Replimune Group by 19.9% during the first quarter. Victory Capital Management Inc. now owns 691,212 shares of the company’s stock worth $12,207,000 after acquiring an additional 114,725 shares during the last quarter. Sectoral Asset Management Inc. raised its position in shares of Replimune Group by 33.4% during the first quarter. Sectoral Asset Management Inc. now owns 262,200 shares of the company’s stock worth $4,630,000 after acquiring an additional 65,700 shares during the last quarter. Moody Aldrich Partners LLC grew its stake in shares of Replimune Group by 21.1% during the second quarter. Moody Aldrich Partners LLC now owns 106,808 shares of the company’s stock worth $2,480,000 after purchasing an additional 18,610 shares during the period. Barclays PLC grew its stake in shares of Replimune Group by 23.5% during the second quarter. Barclays PLC now owns 113,011 shares of the company’s stock worth $2,624,000 after purchasing an additional 21,482 shares during the period. Finally, Profund Advisors LLC acquired a new stake in shares of Replimune Group during the first quarter worth $712,000. Institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.